HC Wainwright Has Bearish Outlook for CGEM FY2025 Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Cullinan Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($2.74) for the year, down from their previous forecast of ($2.55). HC Wainwright has a "Buy" rating and a $33.00 price target on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q4 2025 earnings at ($0.20) EPS and FY2026 earnings at ($3.15) EPS.

Separately, UBS Group began coverage on shares of Cullinan Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $30.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $32.50.

Cullinan Therapeutics Stock Performance

Shares of CGEM traded up $0.05 during mid-day trading on Monday, hitting $10.35. The company's stock had a trading volume of 1,376,507 shares, compared to its average volume of 517,684. The stock's 50-day moving average is $11.49 and its two-hundred day moving average is $14.96. The firm has a market capitalization of $602.68 million, a PE ratio of -3.64 and a beta of -0.16. Cullinan Therapeutics has a one year low of $9.50 and a one year high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.09.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in Cullinan Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 430,971 shares of the company's stock valued at $5,249,000 after purchasing an additional 7,012 shares in the last quarter. New York State Common Retirement Fund grew its holdings in shares of Cullinan Therapeutics by 32.9% during the fourth quarter. New York State Common Retirement Fund now owns 12,918 shares of the company's stock worth $157,000 after purchasing an additional 3,200 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Cullinan Therapeutics by 8.5% in the fourth quarter. Rhumbline Advisers now owns 68,208 shares of the company's stock valued at $831,000 after buying an additional 5,348 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Cullinan Therapeutics by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,346 shares of the company's stock valued at $150,000 after buying an additional 1,195 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Cullinan Therapeutics during the 4th quarter worth about $136,000. Institutional investors own 86.31% of the company's stock.

Insider Buying and Selling

In other news, CEO Nadim Ahmed sold 8,400 shares of the company's stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $11.87, for a total value of $99,708.00. Following the sale, the chief executive officer now owns 263,150 shares of the company's stock, valued at approximately $3,123,590.50. This represents a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jennifer Michaelson sold 4,693 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $11.41, for a total transaction of $53,547.13. Following the sale, the insider now owns 99,760 shares of the company's stock, valued at $1,138,261.60. This trade represents a 4.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,582 shares of company stock valued at $246,977 over the last ninety days. 6.07% of the stock is owned by company insiders.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.